
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The... Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease, multiple sclerosis and rare neurodegenerative diseases. The company's current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1607 | -10.04375 | 1.6 | 1.67 | 1.2 | 5885942 | 1.46080037 | CS |
4 | 1.2373 | 612.524752475 | 0.202 | 3.9099 | 0.16 | 89875530 | 1.8136773 | CS |
12 | 1.2093 | 525.782608696 | 0.23 | 3.9099 | 0.1135 | 41820759 | 1.37628099 | CS |
26 | 1.0193 | 242.69047619 | 0.42 | 3.9099 | 0.1135 | 20066602 | 1.36070415 | CS |
52 | 0.5954 | 70.5533831023 | 0.8439 | 3.9099 | 0.1135 | 12954290 | 1.3486113 | CS |
156 | 0.5954 | 70.5533831023 | 0.8439 | 3.9099 | 0.1135 | 12954290 | 1.3486113 | CS |
260 | 0.5954 | 70.5533831023 | 0.8439 | 3.9099 | 0.1135 | 12954290 | 1.3486113 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.